Bortezomib (velcade). A new therapy for multiple myeloma

Research output: Contribution to journalReview article

Abstract

Bortezomib (PS341) represents a new class of drugs for the treatment of Multiple Myeloma (MM). PS341 was approved May 2003 for patients with refractory MM. PS341 targets the proteasome, a protease complex, involved in protein degradation and cell cycle regulation. The proteasome has increased activity in various cancers. In MM, proteasome inhibition by PS341 increases the inhibition of Nuclear Factor kappa-B leading to decreased transcription of genes involved in MM growth. In the major Phase II trial, patients with previously treated MM which was resistant to the most recent treatment obtained more than a 30% overall response rate and a 4% complete response rate. This unique activity led to a rapid approval in refractory MM. Because of potential activity in other cancers and perhaps in non-malignant diseases coupled with its cost which exceeds $20,000 per treatment course, it will be important to apply strong evidence based criteria when using PS341 clinically.

Original languageEnglish (US)
Pages (from-to)29-38
Number of pages10
JournalClinical Research and Regulatory Affairs
Volume21
Issue number1
DOIs
StatePublished - Jul 30 2004

Fingerprint

Multiple Myeloma
Proteasome Endopeptidase Complex
Therapeutics
NF-kappa B
Proteolysis
Bortezomib
Neoplasms
Cell Cycle
Peptide Hydrolases
Costs and Cost Analysis
Growth
Pharmaceutical Preparations
Genes

Keywords

  • Bortezomib
  • Multiple myeloma
  • PS341
  • Proteasome inhibition
  • Velcade®

ASJC Scopus subject areas

  • Pharmacology
  • Pharmaceutical Science
  • Pharmacology (medical)

Cite this

Bortezomib (velcade). A new therapy for multiple myeloma. / McGuire, Timothy R.

In: Clinical Research and Regulatory Affairs, Vol. 21, No. 1, 30.07.2004, p. 29-38.

Research output: Contribution to journalReview article

@article{86e4b03453294a0e9114659eb8da5ba9,
title = "Bortezomib (velcade). A new therapy for multiple myeloma",
abstract = "Bortezomib (PS341) represents a new class of drugs for the treatment of Multiple Myeloma (MM). PS341 was approved May 2003 for patients with refractory MM. PS341 targets the proteasome, a protease complex, involved in protein degradation and cell cycle regulation. The proteasome has increased activity in various cancers. In MM, proteasome inhibition by PS341 increases the inhibition of Nuclear Factor kappa-B leading to decreased transcription of genes involved in MM growth. In the major Phase II trial, patients with previously treated MM which was resistant to the most recent treatment obtained more than a 30{\%} overall response rate and a 4{\%} complete response rate. This unique activity led to a rapid approval in refractory MM. Because of potential activity in other cancers and perhaps in non-malignant diseases coupled with its cost which exceeds $20,000 per treatment course, it will be important to apply strong evidence based criteria when using PS341 clinically.",
keywords = "Bortezomib, Multiple myeloma, PS341, Proteasome inhibition, Velcade{\circledR}",
author = "McGuire, {Timothy R}",
year = "2004",
month = "7",
day = "30",
doi = "10.1081/CRP-120034004",
language = "English (US)",
volume = "21",
pages = "29--38",
journal = "Clinical Research Practices and Drug Regulatory Affairs",
issn = "1060-1333",
publisher = "Informa Healthcare",
number = "1",

}

TY - JOUR

T1 - Bortezomib (velcade). A new therapy for multiple myeloma

AU - McGuire, Timothy R

PY - 2004/7/30

Y1 - 2004/7/30

N2 - Bortezomib (PS341) represents a new class of drugs for the treatment of Multiple Myeloma (MM). PS341 was approved May 2003 for patients with refractory MM. PS341 targets the proteasome, a protease complex, involved in protein degradation and cell cycle regulation. The proteasome has increased activity in various cancers. In MM, proteasome inhibition by PS341 increases the inhibition of Nuclear Factor kappa-B leading to decreased transcription of genes involved in MM growth. In the major Phase II trial, patients with previously treated MM which was resistant to the most recent treatment obtained more than a 30% overall response rate and a 4% complete response rate. This unique activity led to a rapid approval in refractory MM. Because of potential activity in other cancers and perhaps in non-malignant diseases coupled with its cost which exceeds $20,000 per treatment course, it will be important to apply strong evidence based criteria when using PS341 clinically.

AB - Bortezomib (PS341) represents a new class of drugs for the treatment of Multiple Myeloma (MM). PS341 was approved May 2003 for patients with refractory MM. PS341 targets the proteasome, a protease complex, involved in protein degradation and cell cycle regulation. The proteasome has increased activity in various cancers. In MM, proteasome inhibition by PS341 increases the inhibition of Nuclear Factor kappa-B leading to decreased transcription of genes involved in MM growth. In the major Phase II trial, patients with previously treated MM which was resistant to the most recent treatment obtained more than a 30% overall response rate and a 4% complete response rate. This unique activity led to a rapid approval in refractory MM. Because of potential activity in other cancers and perhaps in non-malignant diseases coupled with its cost which exceeds $20,000 per treatment course, it will be important to apply strong evidence based criteria when using PS341 clinically.

KW - Bortezomib

KW - Multiple myeloma

KW - PS341

KW - Proteasome inhibition

KW - Velcade®

UR - http://www.scopus.com/inward/record.url?scp=3242735889&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3242735889&partnerID=8YFLogxK

U2 - 10.1081/CRP-120034004

DO - 10.1081/CRP-120034004

M3 - Review article

AN - SCOPUS:3242735889

VL - 21

SP - 29

EP - 38

JO - Clinical Research Practices and Drug Regulatory Affairs

JF - Clinical Research Practices and Drug Regulatory Affairs

SN - 1060-1333

IS - 1

ER -